Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis

被引：0

作者：

Hezode, Christophe

Dore, Gregory J.

Pianko, Stephen

Pol, Stanislas

Stuart, Katherine

Thompson, Alexander

Tse, Edmund

Bhore, Rafia

Jimenez-Exposito, Maria Jesus

机构：

来源：

GASTROENTEROLOGY | 2016年 / 150卷 / 04期

关键词：

D O I：

10.1016/S0016-5085(16)33701-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Su1424

引用

页码：S1096 / S1096

页数：1

共 50 条

[41] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience [J].

Shiha, G. ;

Soliman, R. ;

ElBasiony, M. ;

Hassan, A. A. ;

Mikhail, N. N. H. .

HEPATOLOGY INTERNATIONAL, 2018, 12 (04) :339-347

[42] High Rates of SVR in Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir plus Ribavirin or Ledipasvir/Sofosbuvir+GS-9669 for 8 weeks [J].

Lawitz, Eric ;

Poordad, Fred ;

Hyland, Robert H. ;

Wang, Jing ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Membreno, Fernando E. .

HEPATOLOGY, 2014, 60 :1143A-1143A

[43] Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir plus interferon plus ribavirin and sofosbuvir plus daclatasvir plus ribavirin) [J].

Wahid, Braira ;

Shami, Khadija ;

Joiya, Salman A. ;

Ozuyar, Sevilay E. G. ;

Idrees, Muhammad .

JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) :3868-3870

[44] C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks [J].

Foster, Graham R. ;

Agarwal, Kosh ;

Cramp, Matthew ;

Moreea, Sulleman ;

Barclay, Stephen T. ;

Collier, Jane ;

Brown, Ashley S. ;

Ryder, Stephen D. ;

Ustianowski, Andrew ;

Forton, Daniel M. ;

Fox, Ray ;

Gordon, Fiona ;

Rosenberg, William M. ;

Mutimer, David J. ;

Du, Jiejun ;

Gilbert, Christopher L. ;

Wahl, Janice ;

Barr, Eliav ;

Haber, Barbara .

HEPATOLOGY, 2016, 64 :39A-40A

[45] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM [J].

Petersen, J. ;

Welzel, T. ;

Herzer, K. ;

Ferenci, P. ;

Gschwantler, M. ;

Cornberg, M. ;

Ingiliz, P. ;

Berg, T. ;

Spengler, U. ;

Weiland, O. ;

van der Valk, M. ;

Klinker, H. ;

Rockstroh, J. ;

Peck-Radosavljevic, M. ;

Zhao, Y. ;

Jimenez-Exposito, M. J. ;

Zeuzem, S. .

JOURNAL OF HEPATOLOGY, 2016, 64 :S781-S782

[46] Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection [J].

Gane, Edward J. ;

Hyland, Robert H. ;

An, Di ;

Svarovskaia, Evguenia ;

Pang, Phillip S. ;

Brainard, Diana ;

Stedman, Catherine A. .

GASTROENTEROLOGY, 2015, 149 (06) :1454-+

[47] ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAIVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY [J].

Lalezari, J. P. ;

Nelson, D. R. ;

Hyland, R. H. ;

Lin, M. ;

Rossi, S. J. ;

Symonds, W. T. ;

Rodriguez-Torres, M. ;

Lawitz, E. J. .

JOURNAL OF HEPATOLOGY, 2013, 58 :S346-S346

[48] Sofosbuvir/Ledipasvir plus Ribavirin achieves high SVR12 in genotype-3 patients with compensated cirrhosis and similar to Sofosbuvir plus Daclatasvir. A multicentre real life cohort [J].

Riveiro-Barciela, Mar ;

Alonso, Sonia ;

Fernandez, Inmaculada ;

Rincon, Diego ;

Real, Yolanda ;

Crespo, Javier ;

Gea, Francisco ;

Olveira, Antonio ;

Calleja, Jose L. ;

Lorduy, Benjamin Polo ;

Carrion, Jose Antonio ;

Arenas, Juan ;

Devesa, Maria Jose ;

Baliellas, Carme ;

Castro, Angeles ;

Romero-Gomez, Manuel ;

Granados, Rafael ;

Pascasio, Juan Manuel ;

Prieto, Martin ;

Salmeron, Javier ;

Badia, Ester ;

Moreno, Jose M. ;

Forns, Xavier ;

Turnes, Juan ;

Montero, Jose Luis ;

Esteban, Rafael ;

Fernandez-Rodriguez, Conrado M. .

HEPATOLOGY, 2016, 64 :464A-464A

[49] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus [J].

McEwan, Phil ;

Webster, Samantha ;

Ward, Thomas ;

Brenner, Michael ;

Kalsekar, Anupama ;

Yuan, Yong .

COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15

[50] Effect of Ribavirin on the Safety Profile of Daclatasvir Plus Sofosbuvir for Patients With Chronic HCV Infection Presidential Poster [J].

Sulkowski, Mark ;

Gardiner, David ;

Hughes, Eric ;

Huang, Shu-Pang ;

Grasela, Dennis .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 :S169-S169

← 1 2 3 4 5 →